Thermo Fisher Scientific Inc (NYSE:TMO) has been given an average recommendation of “Buy” by the eighteen research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, sixteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $188.56.

A number of research firms recently weighed in on TMO. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 target price for the company in a report on Tuesday, August 1st. BidaskClub lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Bank of America Corporation reissued a “buy” rating and issued a $210.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Thursday, July 20th. Finally, Barclays PLC reissued an “overweight” rating and issued a $200.00 target price (up from $190.00) on shares of Thermo Fisher Scientific in a report on Monday, July 17th.

Shares of Thermo Fisher Scientific (NYSE:TMO) traded up 0.87% during midday trading on Friday, hitting $173.23. 2,202,642 shares of the stock were exchanged. The firm’s 50-day moving average is $176.78 and its 200 day moving average is $165.46. The firm has a market cap of $67.58 billion, a PE ratio of 30.18 and a beta of 1.06. Thermo Fisher Scientific has a 52-week low of $139.07 and a 52-week high of $182.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The business had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. During the same period last year, the firm posted $2.03 EPS. The company’s revenue was up 10.2% on a year-over-year basis. On average, analysts forecast that Thermo Fisher Scientific will post $9.24 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be given a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.

TRADEMARK VIOLATION NOTICE: “Thermo Fisher Scientific Inc (TMO) Given Average Rating of “Buy” by Analysts” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/11/thermo-fisher-scientific-inc-tmo-given-average-rating-of-buy-by-analysts.html.

In related news, insider Daniel P. Shine sold 4,688 shares of the firm’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $171.88, for a total value of $805,773.44. Following the completion of the sale, the insider now directly owns 29,200 shares in the company, valued at $5,018,896. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $176.26, for a total value of $440,650.00. Following the completion of the sale, the chief financial officer now owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,188 shares of company stock valued at $4,702,223. 0.49% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in TMO. Independent Portfolio Consultants Inc. increased its stake in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares during the period. Sharkey Howes & Javer increased its stake in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after buying an additional 7 shares during the period. Washington Trust Bank increased its stake in Thermo Fisher Scientific by 0.5% in the first quarter. Washington Trust Bank now owns 2,210 shares of the medical research company’s stock valued at $339,000 after buying an additional 10 shares during the period. Beacon Trust Co. increased its stake in Thermo Fisher Scientific by 0.6% in the first quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock valued at $341,000 after buying an additional 12 shares during the period. Finally, Dumont & Blake Investment Advisors LLC increased its stake in Thermo Fisher Scientific by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 5,526 shares of the medical research company’s stock valued at $849,000 after buying an additional 15 shares during the period. Institutional investors and hedge funds own 87.15% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.